

Raymond Jia, General Manager, Acrostar SMO & Daniel Kim, SMO Director
In the fast-moving world of drug development, sponsors are under constant pressure to deliver results faster—without compromising quality or compliance. While Contract Research Organizations (CROs) oversee global trial operations, Site Management Organizations (SMOs) have emerged as a powerful partner in improving trial efficiency at the ground level.
For biotech and pharmaceutical companies, an experienced SMO can be the difference between delayed recruitment and on-time database lock.
A Site Management Organization (SMO) provides direct operational and administrative support to clinical trial sites. This includes patient recruitment and retention, regulatory documentation, investigator training, and ongoing quality oversight. By managing these complex, time-intensive activities, SMOs enable sponsors and CROs to focus on strategy and data while ensuring that every trial site performs to the highest standards.
In essence, SMOs connect global strategy with local site precision, transforming clinical trial operations into measurable results.
Enrollment remains one of the greatest challenges in clinical trials. SMOs leverage site networks, patient databases, and community engagement strategies to recruit eligible patients quickly and keep them engaged throughout the study. This targeted, data-driven approach reduces recruitment timelines and improves retention rates, two critical drivers of trial success.
SMOs maintain consistent Good Clinical Practice (GCP) training and provide real-time oversight of documentation and site performance. This ensures each site meets global regulatory standards, reducing the risk of audit findings and data inconsistencies.
By managing scheduling, reporting, and communication between investigators and CROs, SMOs remove many of the operational bottlenecks that slow trial progress. Sponsors benefit from greater efficiency, lower administrative cost, and improved visibility into site performance.
In regions like Asia-Pacific, where healthcare systems and patient populations vary widely, SMOs bring critical local knowledge. Their understanding of cultural, linguistic, and regulatory nuances enables faster trial initiation and smoother collaboration with investigators.
Acrostar, a Novotech company, is a leading Site Management Organization providing full-service site operation support across Asia.
Its specialized capabilities include:
With strong partnerships across Asia’s most active research hubs, Acrostar combines local operational expertise with global quality standards.
Acrostar offers sponsors a fully integrated model that delivers:
Together, Novotech and Acrostar give biotech and pharma companies the advantage of global oversight with local precision a critical factor in today’s competitive clinical landscape.
As clinical research becomes more complex, sponsors are increasingly seeking integrated CRO–SMO partnerships. This model ensures strategic continuity from protocol to patient, enhancing data quality and accelerating delivery timelines. For sponsors pursuing efficiency, reliability, and scalability, partnering with a unified network like Novotech and Acrostar provides a clear competitive edge: Global reach. Local expertise. Faster results.